Pending Approvals Hold Major Implications For Myozyme Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme reports increasing sales for Pompe disease drug, but upcoming EU and FDA decisions could spur or stifle product’s growth.